ACHV·Canada·Healthcare
Share

Achieve Life Sciences, Inc.

$ 2.22

Achieve Life Sciences, Inc.

Share
ACHV·Canada·Healthcare

$ 2.22

Rating

2

Buy

Risk factor

Very high price volatility

Weak & very vulnerable to price shocks

Significant default risk

Profitability factor

Slightly undervalued vs peers

Very low or no dividends

Very poor margins and returns

Risk / Profitability

Risk: High

Profitability: Average

About

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has...

About

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

Risk factor

Very high price volatility

Weak & very vulnerable to price shocks

Significant default risk

Profitability factor

Slightly undervalued vs peers

Very low or no dividends

Very poor margins and returns

$ 2.22

About

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has...

About

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.

X-channel